Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04739-2
In the STOP-V1 and STOP-V2 trials, povorcitinib (an oral JAK1 inhibitor) was superior to placebo in improvement in F-VASI75 score in individuals with nonsegmental vitiligo.
